Published in PLoS One on March 28, 2013
Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation (2013) 1.13
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. Hum Gene Ther (2016) 0.84
Isolation Housing Exacerbates Alzheimer's Disease-Like Pathophysiology in Aged APP/PS1 Mice. Int J Neuropsychopharmacol (2015) 0.78
Inhibition of human high-affinity copper importer Ctr1 orthologous in the nervous system of Drosophila ameliorates Aβ42-induced Alzheimer's disease-like symptoms. Neurobiol Aging (2013) 0.77
Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications. Mol Neurobiol (2014) 0.77
Creating anatomically accurate and reproducible intracranial xenografts of human brain tumors. J Vis Exp (2014) 0.75
Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking. J Immunol Methods (2016) 0.75
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (2002) 5.30
Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med (2000) 4.99
Metabolic regulation of brain Abeta by neprilysin. Science (2001) 4.47
Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron (2003) 4.11
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci (2003) 2.44
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci (2003) 2.28
Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol (2008) 2.26
Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci (1993) 2.12
Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett (1994) 1.99
Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol (2002) 1.89
Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem (2002) 1.87
Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging (2005) 1.68
Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci (2004) 1.65
Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J Biol Chem (2001) 1.63
Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol (2004) 1.58
Generation and characterization of chimeric recombinant AAV vectors. Mol Ther (2003) 1.54
Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res (2000) 1.46
Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol (2003) 1.44
Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci (2010) 1.42
Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol (2007) 1.32
Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging (2006) 1.32
Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2008) 1.30
Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res (2001) 1.30
Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J Neurochem (2010) 1.24
Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. BMC Neurosci (2008) 1.20
Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res (1997) 1.20
Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Mol Ther (2008) 1.17
Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther (2006) 1.06
Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods (2010) 1.02
A monomeric variant of insulin degrading enzyme (IDE) loses its regulatory properties. PLoS One (2010) 0.93
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci (2003) 2.44
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 2.38
Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. Eur Heart J (2007) 2.26
Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc (2006) 2.12
Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology (2007) 2.11
Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci (2009) 2.05
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging (2004) 1.97
Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol (2005) 1.90
Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol (2002) 1.89
Estimation of distribution algorithm for resource allocation in green cooperative cognitive radio sensor networks. Sensors (Basel) (2013) 1.79
Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci (2006) 1.79
Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci (2003) 1.76
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis (2004) 1.73
New insights into chimpanzees, tools, and termites from the Congo Basin. Am Nat (2004) 1.71
Correspondence between the 17-segment model and coronary arterial anatomy using contrast-enhanced cardiac magnetic resonance imaging. JACC Cardiovasc Imaging (2008) 1.70
Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A (2008) 1.66
Myosin-binding protein C phosphorylation, myofibril structure, and contractile function during low-flow ischemia. Circulation (2005) 1.59
Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol (2004) 1.58
Determinants of myocardial salvage during acute myocardial infarction: evaluation with a combined angiographic and CMR myocardial salvage index. JACC Cardiovasc Imaging (2010) 1.57
The Cardiac Atlas Project--an imaging database for computational modeling and statistical atlases of the heart. Bioinformatics (2011) 1.44
Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther (2011) 1.43
Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci (2010) 1.42
LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation (2010) 1.40
Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol (2007) 1.32
Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc (2006) 1.18
Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med (2004) 1.17
Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Mol Ther (2008) 1.17
Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiol Aging (2013) 1.16
Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia (2006) 1.16
The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease. J Neurosci (2012) 1.14
Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation (2013) 1.13
Phosphorylation dynamics regulate Hsp27-mediated rescue of neuronal plasticity deficits in tau transgenic mice. J Neurosci (2010) 1.13
Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. J Neurochem (2004) 1.13
A collaborative resource to build consensus for automated left ventricular segmentation of cardiac MR images. Med Image Anal (2013) 1.13
Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Brain Res Rev (2005) 1.11
Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J Neuropathol Exp Neurol (2003) 1.10
Virtual electrophysiological study in a 3-dimensional cardiac magnetic resonance imaging model of porcine myocardial infarction. J Am Coll Cardiol (2012) 1.09
Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J (2009) 1.08
Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. J Histochem Cytochem (2004) 1.08
Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A (2007) 1.04
Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging (2013) 1.02
Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods (2010) 1.02
Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. ASN Neuro (2011) 1.01
Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci (2007) 1.00
Traumatic ventricular septal defect. Ann Thorac Surg (2011) 1.00
Chaperone signalling complexes in Alzheimer's disease. J Cell Mol Med (2009) 0.99
Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflammation (2006) 0.97
Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci (2004) 0.97
"Shades of gray" in cardiac magnetic resonance images of infarcted myocardium: can they tell us what we'd like them to? Circulation (2006) 0.96
Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence. J Neuroinflammation (2011) 0.95
Interaction of NG2(+) glial progenitors and microglia/macrophages from the injured spinal cord. Glia (2010) 0.94
Systemic sclerosis and the heart: current diagnosis and management. Curr Opin Rheumatol (2011) 0.93
Left atrial flow velocity distribution and flow coherence using four-dimensional FLOW MRI: a pilot study investigating the impact of age and Pre- and Postintervention atrial fibrillation on atrial hemodynamics. J Magn Reson Imaging (2013) 0.92
Atlas-based analysis of cardiac shape and function: correction of regional shape bias due to imaging protocol for population studies. J Cardiovasc Magn Reson (2013) 0.91
Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. PLoS One (2013) 0.90
Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neurosci (2005) 0.89
Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. J Neurosci (2009) 0.89
Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008). Behav Neurosci (2008) 0.87
Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice. J Alzheimers Dis (2008) 0.85
Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. Neurobiol Aging (2007) 0.85
Deficiency of complement factor MBL in a patient required cardiac surgery after an acute myocardial infarction with underlining chronic lymphocytic leukemia. Int J Cardiol (2008) 0.85
Purification, crystallization and preliminary X-ray analysis of isocitrate dehydrogenase kinase/phosphatase from Escherichia coli. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.85
Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol (2008) 0.85